SML2694
FB23-2
≥98% (HPLC)
Sinonimo/i:
2-[[2,6-Dichloro-4-(3,5-dimethyl-4-isoxazolyl)phenyl]amino]-N-hydroxybenzamide
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Prodotti consigliati
Livello qualitativo
Saggio
≥98% (HPLC)
Forma fisica
powder
Colore
white to beige
Solubilità
DMSO: 2 mg/mL, clear
Temperatura di conservazione
2-8°C
Stringa SMILE
ClC1=C(NC2=C(C(NO)=O)C=CC=C2)C(Cl)=CC(C3=C(C)ON=C3C)=C1
Azioni biochim/fisiol
FB23-2 can also prevent osteogenic differentiation of human mesenchymal stem cells (MSCs). It is capable of delaying leukemogenesis in vivo. In mice, FB23-2 at a dose of 20 mg/kg is safe for testing in vivo efficacy.
FB23-2 is a cell penetrant, potent and specific inhibitor of N6-methyladenosine (m6A) demethylase FTO (fat mass and obesity associated protein) that RNA methylation in varies of AML cells. FB23-2 potently inhibits proliferation and promotes apoptosis and differentiation in human acute myeloid leukemia (AML) cells and primary blast AML cells lines and xenografts in mice. It minimally affects proliferation of human normal bone marrow cells.
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Cancer cell, 35(4), 677-691 (2019-04-17)
FTO, an mRNA N6-methyladenosine (m6A) demethylase, was reported to promote leukemogenesis. Using structure-based rational design, we have developed two promising FTO inhibitors, namely FB23 and FB23-2, which directly bind to FTO and selectively inhibit FTO's m6A demethylase activity. Mimicking FTO
The m6A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG.
Acta pharmacologica Sinica, 43(5), 1311-1323 (2021-09-01)
N6-methyladenosine (m6A) is the most abundant posttranscriptional methylation modification that occurs in mRNA and modulates the fine-tuning of various biological processes in mammalian development and human diseases. In this study we investigated the role of m6A modification in the osteogenesis
Cancer cell, 35(4), 677-691 (2019-04-17)
FTO, an mRNA N6-methyladenosine (m6A) demethylase, was reported to promote leukemogenesis. Using structure-based rational design, we have developed two promising FTO inhibitors, namely FB23 and FB23-2, which directly bind to FTO and selectively inhibit FTO's m6A demethylase activity. Mimicking FTO
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.